Urinary Incontinence Flashcards

1
Q

Stress as a form of urinary incontinence

A

Urine leaks out during any form of exertion (e.g.,exercise,coughing, sneezing, laughing) as a result of pressure on the bladder.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Urge as a form of urinary incontinence. associated with? present in which population?

A

A sudden and unstoppable urge to urinate. Associated with neuropathy and often present in those with diabetes, strokes, dementia, Parkinson disease or multiple sclerosis (although people without comorbidities can be affected).

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Mixed

A

Combination of urge and stress

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

functional

A

There is no abnormality in the bladder, but the patient may be cognitively, socially or physically impaired thus hindering accessto a toilet (e.g.,patients in wheelchairs).

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Urinary urgency

A

a sudden feeling of needing to urinate. This is the primary symptom of OAB; it can occur with or without incontinence and is usually accompanied by urinary frequency and nocturia.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Urinary frequency

A

voiding >= 8 times during waking hours.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Nocturia

A

> = 2 awakenings in the night to urinate

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Urinary Incontinence

A

involuntary leakage of urine (see table for different forms).

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

OAB wet

A

about 1/3 patients with OAB have incontinent episodes

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

OAB dry

A

abour 2/3 patients with OAB do not have incontinence episode

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

What are the comorbidities that exist in patients with OAB

A

falls and fractures, skin breakdown and skin infections, UTis, depression and sexual dysfunction.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Social implications of OAB

A

Due to the embarrassment of the condition, there are many social implications of OAB, including low self-esteem, lack of sexual intimacy, social and physical isolation, sleep disturbances, limits on travel and dependence on caregivers. These can lead to a reduced quality of life. Many patients become dehydrated because they limit fluid intake. The cost of pads and adult diapers can cause a financial burden.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

The detrusor muscle is innervated by:

A

the parasympathetic nervous system: ACH acting on Muscarinic receptor

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

the bladder neck is innervated by the

A

Sympathetic Nervous System

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Internal and External sphincter innervated by:

A

Internal: sympathetic
External: Somatic

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

both voluntary and involuntary contractions of the detrusor muscle are mediated by:

A

Ach activation of muscarinic receptors

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

What happens in OAB

A

there is an inappropriate stimulation of the muscarinic receptors on the detrusor muscle causing involuntary contractions and the feeling of urinary urgency –> this is a contraction of the bladder even when its not full

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

Human bladder muscarinic receptor subtypes:

A

M2 and M3 in a 3:1 ratio

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

M3 receptor is responsible of:

A

emptying contractions and involuntary bladder contractions

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

What are the risk factors for an OAB?

A

1- Age >40
2- Diabetes
3- Prior vaginal delivery
4- Obesity
5- Neurologic conditions (parkinson, stroke, dementia)
6- drugs that increase incontinence (alcohol- cholinesterase inhibitors- diuretics- sedatives)
7- restricted mobility
8- hysterectomy
9- pelvic injury

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

What are non-drug treatments of AOB?

A

Behavioral therapies are considered first-line to improve OAB symptoms. These include:

  • bladder training
  • delayed or scheduled voiding
  • pelvic floor muscle exercises (Kegel exercises)
  • urge control techniques (distraction, self- assertions)
  • fluid management
  • dietary changes (avoiding bladder irritants)
  • weight loss and other lifestyle measures (e.g., stopping medications that can worsen OAB; or with diuretics, changing the time of administration to avoid nocturia).
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

Can behavioral be combined with other treatment modalities? (medications or surgical interventions)

A

yes: medications
Surgical interventions should be reserved for the rare non-neurogenic patient who has failed all other therapeutic options and whose symptoms are intolerable.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

What is technique of Kegel exercices

A

Instruct the patient to imagine that they are trying to stop urination midstream. Squeeze the muscles they would use. If they sense a “pulling” feeling, those are the correct muscles for pelvic exercise. Pull in the pelvic muscles and hold for a count of three, then relax for a count of three. Patients should work up to three sets of 10 exercises per day to reduce wetting episodes.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

Drug treatment

A

A step-wise approach is recommended that begins conservatively with behavioral therapy (see previous section). Treatment depends on the degree of severity felt by the patient; with severe symptoms, treatment can begin at a higher level (see algorithm). Drugs are added to the behavioral recommendations (e.g., Kegel exercises, bladder training, weight loss), when needed.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
25
Q

Urge incontinence/ Mixed incontinence drug treatment:

A

Mixed incontinence has an urge incontinence component and is treated in a similar manner.

First-line drugs include:
–> anticholinergics (e.g., oxybutynin) or a beta-3 receptor agonist (e.g., mirabegron). OnabotulinumtoxinA (Botox) has higher efficacy but is NOT first-line due to cost and the route of administration through the urethra and into the detrusor muscle.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
26
Q

Nerve stimulation or surgical intervention in urge incontinence/mixed?

A

Used last

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
27
Q

Women with postmenopausal symptoms of vulvar and vaginal atrophy

A

can use vaginal estrogen in a cream or a ring, which may provide modest relief of symptoms. Estrogen is not FDA-approved for this purpose.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
28
Q

Drug Algorithm

A

A -BEHAVIORAL + ANTICHOLI OR BETA3 AGONIST

1- An adequate drug trial of 4-8 weeks is recommended before modifying treatment or adding a second drug.

2- A long-acting anticholinergic, such as oxybutynin ER or transdermal (Oxytrol}, is often used initially.

  • Long-acting formulations have less side effects (less dry mouth, dry/blurry vision, constipation) but can cause cognitive impairment.
  • Selective anticholinergics (darifenacin, solifenacin) have less cognitive side effects.
  • Generics (e.g., oxybutynin) have lower cost.

3- Mirabegron (beta-3 agonist) has similar efficacy to the anticholinergics, with different side effects: GI upset, dizziness, headache and increased BP

B- OnabotulinumtoxinA injection: higher efficacy- expensive and requires injection

C- Nerve stimulation and surgical treatment

29
Q

Stress Incontinence Medications

A

The medications used for stress incontinence are not FDA-approved for this use and have minimal efficacy, but there is a lack of more effective options.

Pseudoephedrine, an agonist of norepinephrine (NE) and epinephrine (Epi), causes adrenaline- type effects, including tachycardia, palpitations, nervousness/anxiety, headache and insomnia.

Duloxetine is commonly chosen when it is possible to treat two conditions with one drug (e.g., incontinence/depression), though it has little efficacy for incontinence (see the Depression chapter).

30
Q

Anticholinergic Drugs
MOA ?
Which formulations are preferred and why?

A

Anticholinergic drugs, also called antimuscarinic drugs, competitively bind to muscarinic receptors and block acetylcholine from binding.
-> This limits contractions of the detrusor muscle.

ER formulations are preferred over IR formulations due to a lower risk of dry mouth.

Drugs that are more selective for the M3 receptor (solifenacin, darifenacin and fesoterodine) have fewer CNS side effects than the older, non-selective drugs, such as oxybutynin.

31
Q

Anticholinergics in patients age 65 and older?

A

The Beers Criteria recommend avoiding anticholinergics in patients aged 65 years and older, due to a risk of delirium and cognitive impairment.

32
Q

Selective M3 anticholi

A

Solifenacin (Vesicare)
Darifenacin
Fesoterodine

33
Q

Oxybutynin forms

A

Anticholionergic Drug

IR
ER: Ditropan XL
PATCH: (Oxytrol- Rx, Oxytrol for Women-OTC): Apply 1 patch twice weekly (changed every 4 days)
Oxybutynin 10% topical GEL

34
Q

Tolterodine

A

Anticholinergic drug
Tolterodine ( Detrol )
Teltererodine ER: Detrol LA

35
Q

Trospium

A

Anticholinergic drug
Take on an empty stomach

36
Q

Contraindications of Anticholinergic Drugs

A

Uncontrolled narrow angle glaucoma
urinary retention
gastric retention
decreased gastric motility

Oxytrol for Women OTC:
- pain or burning when urinating
- blood in urine
- unexplained lower back or side pain
- cloudy or foul-smelling urine
- male sex
- age< 18 years
- urinary or gastric retention
- glaucoma
- accidental urine loss only due to coughing, sneezing or laughing

37
Q

Warning with Anticholinergics

A

Agitation, confusion, drowsiness, dizziness, blurred vision, hallucinations, and/or headache, which may impair physical or mental abilities; use caution if performing tasks which require mental alertness (e.g.,operating machinery, driving)

Angioedema of the face, lips, tongue and/or larynx

38
Q

SE of anticholinergics

A

Dizziness and drowsiness (greatest with oxybutynin and less with the newer, selective drugs)
xerostomia (dry mouth)
constipation
dry eyes/blurred vision
urinary retention
application site reactions (with topical gel and patch)

39
Q

If Crcl <30, what anticholi drugs need to be adjusted?

A

decrease dose in renal impairment (CrCI < 30 ml/min) with:
fesoterodine, solifenacin (Vesicare), tolterodine, and trospium (do not use trospium XR)

40
Q

Which Anticholinergic drug is an OROS (osmotic-controlled release oral delivery system formulation) and can leave a ghost shell (empty shell) in the stool ?

A

Ditropan XL (Oxybutynin ER)

41
Q

Which Oxybutynin formulations can cause less dry mouth and constipation

A

Patch and gel can cause less dry mouth and constipation than oral forms

42
Q

How do you use Oxytrol Patch?
Does it need to be removed before MRI ?
what about Gelnique?

A

Oxytrol patch should be placed on dry, intact skin on the abdomen, hips or buttocks; avoid reapplication to the same site within 7 days; available OTC for women >= 18 years

Package labeling is not clear if metals may be present in Oxytrol patch (Rx and OTC); consider removing before MRI
Gelnique should be applied to dry, intact skin on the abdomen, thighs or upper arms/ shoulders; rotate application sites (do not use same site on consecutive days)

43
Q

Anticholinergic side effects are divided into 2

A

Peripheral:
Dry mouth
Dry eyes/Blurred vision
Urinary retention
Constipation

Central:
Sedation
Dizziness
Cognitive Impairment

44
Q

Patients fail to comply with anticholinergics because of dry mouth. what can we do?

A

Choosing a treatment that minimizes dry mouth can improve adherence.

  • Try ER formulations (lower risk than IR formulations).
  • Try oxybutynin gel or patch {lower risk than oral formulations).
  • Mirabegron has a lower incidence of dry mouth and can be helpful in patients who cannot tolerate anticholinergics.
  • Try non-drug options to help with symptoms: avoid mouthwashes with alcohol, use ice chips, water, sugar-free candy or gum.
45
Q

Anticholinergic DDI

A

Additive effects can be seen when used with other medications that have anticholinergic side effects.

The lowest dose of tolterodine, solifenacin, darifenacin and fesoterodine should be used if the patient is taking strong CYP450 3A4 inhibitors.

Acetylcholinesterase inhibitors used for dementia (e.g., donepezil) increase acetylcholine in the CNS. Although OAB drugs primarily stay in the periphery (outside the CNS), some patients can experience CNS side effects (e.g., memory impairment).
While this is not a drug interaction, use of anticholinergic drugs can worsen dementia symptoms. The risk versus benefit must be considered.

46
Q

Beta 3 Agonists effect in OAB and what are they.

A

Beta-3 agonists relax the detrusor muscle and increase bladder capacity by activating beta-3 receptors. Mirabegron and Vibegron have similar efficacy to anticholinergic drugs but cause less dry mouth. They can be used in combination with anticholinergic drugs or as monotherapy.

47
Q

Mirabegron

A

Myrbetriq

25-50 mg PO daily
CrCI 15-29 ml/min: 25 mg daily
CrCI < 15 ml/min: not recommended

48
Q

Vibegron

A

Gemtesa

75 mg PO daily

49
Q

Warnings with beta 3 agonists

A
  • Urinary retention in patients with BPH and when used with anticholinergic drugs;
  • increased BP

Mirabegron: angioedema of the face, lips, tongue and/or larynx

50
Q

SE of beta 3 agonists

A

Nasopharyngitis, headache, constipation, diarrhea, dizziness Mirabegron: UTI

51
Q

what do we monitor with Beta 3 agonists. When do we see efficacy?

A

Urinary symptoms
mirabegron: BP
efficacy seen in within 8 weeks

52
Q

Beta-3 Agonist Drug Interactions

A

Mirabegron is a moderate CYP2D6 inhibitor. Use caution in combination with narrow therapeutic drugs metabolized by CYP2D6.

Levels of metoprolol are increased when co-administered with mirabegron.

Levels of tamoxifen are decreased when co-administered with mirabegron. (tamoxi is metabolized by cyp2d6 into its active form)

Use caution in combination with digoxin (use low best digoxin dose and monitor levels).

53
Q

ONABOTULINUMTOXINA (BOTOX)

A

Botox is a third-line treatment for patients who are refractory to first- and second-line treatment options. It affects the detrusor activity by inhibiting the release of acetylcholine.

54
Q

OnabotulinumtoxinA (Botox) doses

A

100 units total dose, administered as 0.5 ml
(5 units) injections, across 20 sites (given intradetrusor) - repeat no sooner than 12 weeks from previous administration

In adults treated with Botox for more than one indication, do not exceed a total dose of 360 units in a 3-month interval

55
Q

Boxed warning of botox

A

All botulinum toxin products may spread from the area of injection to produce symptoms consistent with botulinum toxin effects; swallowing and breathing difficulties can be life-threatening

56
Q

CI of botox

A

Infection at the targeted injection site, urinary tract infection, urinary retention

57
Q

SE of botox

A

Urinary tract infection, urinary retention, dysuria

58
Q

monitoring of botox

A

Post void residual volume, symptoms of OAB

59
Q

is potency of botox interchangeable with other preps of botulinom toxin products?

whats the role of abx

A

Potency units of Botox are not interchangeable with other preparations of botulinum toxin products

Prophylactic antimicrobial therapy (excluding aminoglycosides) should be administered 1-3 days prior to, on the day of, and for 1-3 days following Botox administration

60
Q

DDI of botox

A

Aminoglycosides and drugs affecting neuromuscular transmission can increase the side effects of Botox.

61
Q

Nocturia treatment

A

The only medication FDA-approved for the treatment of nocturia in adults is desmopressin, an antidiuretic hormone analog that temporarily decreases urine production.
It is administered before bed to prevent patients from having to urinate during the night.

62
Q

Desmopressin formulations and uses

A

Desmopressin tablet (DDAVP)

SLtablet (Nocdurna)

Nasal spray (DDAVP,DDAVP Rhinal Tube,Stimate)

Injection (DDAVP)
Diabetes insipidus - DDAVP Rhinal Tube,DDAVPtablet, nasal spray, injection

Hemophilia A- DDAVP injection, Stimate

von Willebrand’s disease- DDAVPinjection, Stimate

63
Q

Desmopressin doses

A

0.2-0.6 mg at bedtime
Females:27.7 mcg 1 hour before bedtime
Males: 55.3 mcg 1 hour before bedtime

64
Q

Desmopressin BOXED WARNING

A

Severe, life-threatening hyponatremia can develop

65
Q

Desmopressin Contraindications

A

Patients with increased risk of severe hyponatremia (e.g., excessive fluid intake, illnesses or drugs that can cause fluid or electrolyte imbalances, including chronic kidney disease, SIADH, loop diuretics, systemic or inhaled glucocorticoids)

  • Patients with increased risk of fluid retention (e.g., uncontrolled hypertension, heart failure)
66
Q

Warning of Desmopressin

A

Do not use with nasal conditions (nasal spray)

67
Q

SE of desmopressin

A

Hyponatremia, headache, hypertension, xerostomia (Nocdurna)

68
Q

monitoring of desmopressin

A

Serum Na (baseline, 1 week and 1 month)